Table 1 Some epidemiological and clinical parameters among the ABO group
From: ABO groups can play a role in susceptibility and severity of COVID-19
A+ (366) | A− (15) | B+ (18) | AB+ (11) | O+ (94) | ||
|---|---|---|---|---|---|---|
Age | 54.5 ± 11 | 51.9 ± 4 | 52.1 ± 6 | 52 ± 9 | 54.7 ± 8 | 53.2 ± 7 |
Sex | ||||||
Male | 212 | 9 | 11 | 6 | 63 | 2 |
Female | 154 | 6 | 7 | 5 | 31 | 1 |
BMI | 25 ± 4 | 24.5 ± 5 | 24 ± 3 | 23 ± 7 | 24.1 ± 5 | 24.4 ± 6 |
Smoking history | ||||||
Non | 87 (23.7%) | 4 (26.7%) | 7 (38.9%) | 4 (36.3%) | 24 (25.5%) | 1 (33.4%) |
Mild | 128 (34.9%) | 5 (33.3%) | 4 (22.3%) | 3 (27.2%) | 33 (35.1%) | 1 (33.4%) |
Moderate | 90 (24.5%) | 3 (20%) | 4 (22.3%) | 3 (27.2%) | 21 (22.3%) | 1 (33.3%) |
Heavy | 61 (16.7%) | 3 (20%) | 3 (16.7%) | 1 (9.3%) | 16 (17.1%) | – |
Comorbidity | ||||||
No comorbidity | 57 (15.5%) | 3 (20%) | 3 (16.7%) | 4 (36.3%) | 41 (43.6%) | 1 (33.3%) |
HTN | 202 (55.2%) | 8 (53.4%) | 6 (33.4%) | 8 (72.7%) | 20 (21.2%) | – |
DM | 198 (54%) | 6 (40%) | 5 (27.8%) | 8 (72.7%) | 22 (32.4%) | 2 (66.7%) |
IHD | 119 (32.5%) | 3 (20%) | 2 (11%) | 2 (18.1%) | 15 (15.9%) | – |
CVA | 177 (48.3%) | 2 (13.4%) | 2 (11%) | 4 (36.2%) | 7 (7.4%) | – |
Chronic chest disease | 25 (6.8%) | 1 (6.7%) | – | 1 (9%) | 12 (12.7%) | – |
Bronchial asthma | 17 (68%) | 1 (100%) | – | – | 8 (66.7) | – |
Bronchiectasis | 8 (32%) | – | – | 1 (100%) | 4 (33.3%) | – |
Severity of COVID-19 | ||||||
Mild low risk | 280 (76.5%) | 6 (40%) | 9 (50%) | 3 (27.2%) | 51 (54.2%) | 2 (66.7%) |
Mild at risk | 18 (4.9%) | 1 (6.7%) | 2 (11.1%) | 3 (27.2%) | 23 (24.4%) | – |
Moderate | 30 (8.1%) | 1 (6.7%) | 3 (16.7%) | 3 (27.2%) | 10 (10.6%) | 1 (33.3%) |
Severe | 12 (3.2%) | 3 (20%) | 1 (5.5%) | 1 (9%) | 5 (5.3%) | – |
Critical | 26 (7.1%) | 4 (26.7%) | 2 (11.1%) | 1 (9%) | 3 (3.1%) | – |
MV | 22 (5.9%) | 2 (13.4%) | 2 (11.1%) | 1 (9%) | 1 (1%) | – |
Outcome | ||||||
Died | 16 (4.37%) | – | 1 (5.5%) | – | 1 (1%) | – |